1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson

Plenary Session

English - April 04, 2019 16:25 - 59 minutes - 60.5 MB - ★★★★★ - 732 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 1.51 BONUS! Study Time Reduction Using Surrogate End Points with Dr. Emerson Chen

Next Episode: 1.53 CALGB 50303, REMoDL-B, & REMS, Orphan Drug Act, and Role of the FDA with Dr. Ameet Sarpatwari

In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer".

BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X
Rivaroxaban: doi.org/10.1056/NEJMoa1814630
Apixaban: doi.org/10.1056/NEJMoa1814468

Back us on Patreon! www.patreon.com/plenarysession